Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 5, 2008, Pages 1618-1622

  Yin, Li Yan ^a   Calhoun, Jason H ^a   Thomas, Jacob K ^a   Shapiro, Stuart ^b   Schmitt Hoffmann, Anne ^b  

^a University of Missouri   (United States)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; LINEZOLID; NOVAPLUS; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; BONE MATRIX; BONE RADIOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL RABBIT; HEMOCONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; TIBIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; BODY WEIGHT; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; OSTEOMYELITIS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIBIA;

EID: 42949105446     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00638-07     Document Type: Article

References (33)

1. Andes, D., and W. A. Craig. 2000. In-vivo pharmacodynamics of RO 63-9141 against multiple bacterial pathogens. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1079.
2. Azoulay-Dupuis, E., J. P. Bédos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111.
3. Bocchini, C. E., K. G. Hulten, E. O. Mason, Jr., B. E. Gonzalez, W. A. Hammerman, and S. L. Kaplan. 2006. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 117:433-440.
4. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
5. Bouza, E., and P. Muñoz. 1999. Micro-organisms responsible for osteo-articular infections. Ballière's Best Pract. Res. Clin. Rheumatol. 13:21-35.
6. Brady, R. A., J. G. Leid, A. K. Camper, J. W. Costerton, and M. E. Shirtliff. 2006. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect. Immun. 74:3415-3426.
7. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
8. Ginzburg, E., N. Namias, M. Brown, S. Ball, S. M. Hameed, and S. M. Cohn. 2000. Gram positive infection in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity. Int. J. Antimicrob. Agents 16(Suppl. 1):S39-S42.
9. Harwood, P. J., and P. V. Giannoudis. 2004. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms. Expert Opin. Drug Safety 3:405-414.
10. Jabés, D., G. Candiani, G. Romanó, C. Brunati, S. Riva, and M. Cavaleri. 2004. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob. Agents Chemother. 48:1118-1123.
11. Leach, K. L., S. M. Swaney, J. R. Colca, W. G. McDonald, J. R. Blinn, L. M. Thomasco, R. C. Gadwood, D. Shinabarger, L. Xiong, and A. S. Mankin. 2007. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell 26:393-402.
12. Lew, D. P. and F. A. Waldvogel. 2004. Osteomyelitis. Lancet 364:369-379.
13. Mader, J. T., and K. Adams. 1989. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. 33:689-692.
14. Mader, J. T., and K. J. Wilson. 1983. Comparative evaluation of cefamandole and cephalothin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. J. Bone Joint Surg. 65:507-513.
15. Murthy, B., and A. Schmitt-Hoffmann. 2008. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47:21-33.
16. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. NCCLS, Wayne, Pa.
17. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, 6th edition. NCCLS, Wayne, Pa.
18. Norden, C. W., and E. A. Gill. 1990. Cefepime for treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J. Infect. Dis. 162:1218-1219.
19. Norden, C. W., K. Niederriter, and E. M. Shinners. 1986. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with teicoplanin. Infection 14:136-138.
20. Norden, C. W., and M. Shaffer. 1983. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J. Infect. Dis. 147:352-357.
21. Patel, R., K. E. Piper, M. S. Rouse, and J. M. Steckelberg. 2000. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob. Agents Chemother. 44:3438-3440.
22. Rayner, C. R., L. M. Baddour, M. C. Birmingham, C. Norden, A. K. Meagher, and J. J. Schentag. 2004. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 32:8-14.
23. Rouse, M. S., K. E. Piper, M. Jacobson, D. J. Jacofsky, J. M. Steckelberg, and R. Patel. 2006. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J. Antimicrob. Chemother. 57:301-305.
24. Schmitt-Hoffmann, A., B. Roos, J. Spickermann, M. Roehrli, and R. Pypstra. 2005. Influence of dose and infusion duration on the time above MIC of BAL9141 in healthy volunteers. Clin. Microbiol. Infect. 11(Suppl. 2):273.
25. Swiontkowski, M. F., D. P. Hanel, N. B. Vedder, and J. P. Schwappach. 1999. A comparison of short- and long-term intravenous antibiotic therapy in the postoperative management of adult osteomyelitis. J. Bone Joint Surg. Br. 81:1046-1050.
26. Tice, A. D., P. A. Hoaglund, and D. A. Shoultz. 2003. Risk factors and treatment outcomes in osteomyelitis. J. Antimicrob. Chemother. 51:1261-1268.
27. Vaudaux, P., A. Gjinovci, M. Bento, D. Li, J. Schrenzel, and D. P. Lew. 2005. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3789-3793.
28. Washington, J. A. 1981. Bactericidal tests, p. 715-728. In J. A. Washington (ed.), Laboratory procedures in clinical microbiology. Springer-Verlag, New York, NY.
29. Wicklow, B. A., M. R. Ogborn, I. W. Gibson, and T. D. Blydt-Hansen. 2006. Biopsy-proven acute tubular necrosis in a child attributed to vancomycin intoxication. Pediatr. Nephrol. 21:1194-1196.
30. Wilson, K. J., and J. T. Mader. 1984. Concentration of vancomycin in bone and serum of normal rabbits and those with osteomyelitis. Antimicrob. Agents Chemother. 25:140-141.
31. Yin, L.-Y., L. Lazzarini, F. Li, C. M. Stevens, and J. H. Calhoun. 2005. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J. Antimicrob. Chemother. 55:995-1002.
32. Yin, L. Y., J. H. Calhoun, T. C. Li, J. Alder, and S. X. Zhang. 2006. Comparative efficacies of vancomycin and Cubicin, a novel lipopeptide antibiotic, in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. Abstr. 44th Infect. Dis. Soc. Am. Annu. Meet., abstr. 358.
33. Yin, L. Y. J. Calhoun, T. Thomas, and E. Wirtz. 2007. Comparative efficacies of telavancin, vancomycin and linezolid in a rabbit model of methicillin-resistant Staphylococcus aureus osteomyelitis. Abstr. 17th ECCMID/25th ICC, Munich, Germany, poster 1769.